{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory&page=65", "query": { "condition": "Relapsed/Refractory", "page": 65 }, "page_size": 10 }, "pagination": { "page": 65, "page_size": 10, "total_count": 3666, "total_pages": 367, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory&page=66&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory&page=64&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-14T15:02:16.383Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07463807", "title": "Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Multiple Myeloma", "Refractory Multiple Myeloma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "FDG-Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Fludeoxyglucose F-18", "type": "OTHER" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Teclistamab", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 162, "start_date": "2027-04-12", "completion_date": "2029-03-31", "has_results": false, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-11-14T15:02:16.383Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07463807" }, { "nct_id": "NCT01199575", "title": "Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia", "CLL" ], "interventions": [ { "name": "Revlimid", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2010-08", "completion_date": "2022-07-19", "has_results": true, "last_update_posted_date": "2024-08-15", "last_synced_at": "2026-11-14T15:02:16.383Z", "location_count": 1, "location_summary": "La Jolla, California", "locations": [ { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01199575" }, { "nct_id": "NCT03674411", "title": "Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Acute Lymphocytic Leukemia", "Biphenotypic/Undifferentiated Leukemia", "Chronic Myelogenous Leukemia", "Myelodysplasia", "Relapsed Large Cell Lymphoma", "Mantle Cell Lymphoma", "Hodgkin Lymphoma", "Burkitt Lymphoma", "Relapsed T-Cell Lymphoma", "Lymphoplasmacytic Lymphoma" ], "interventions": [ { "name": "Fludarabine (FLU)", "type": "DRUG" }, { "name": "Cyclophosphamide (CY)", "type": "DRUG" }, { "name": "Total Body Irradiation (TBI)", "type": "DRUG" }, { "name": "Tacrolimus (Tac)", "type": "DRUG" }, { "name": "Mycophenolate Mofetil (MMF)", "type": "DRUG" }, { "name": "Granulocyte Colony-Stimulating Factor (G-CSF)", "type": "DRUG" }, { "name": "Busulfan (BU)", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "MGTA 456 Infusion", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "55 Years", "sex": "ALL", "summary": "Up to 55 Years" }, "enrollment_count": 22, "start_date": "2019-01-02", "completion_date": "2026-12-01", "has_results": true, "last_update_posted_date": "2026-01-06", "last_synced_at": "2026-11-14T15:02:16.383Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03674411" }, { "nct_id": "NCT03518112", "title": "Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Philadelphia Chromosome Negative", "Recurrent B Acute Lymphoblastic Leukemia", "Refractory B Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Blinatumomab", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Filgrastim", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "BIOLOGICAL" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2018-04-18", "completion_date": "2021-05-27", "has_results": true, "last_update_posted_date": "2022-11-04", "last_synced_at": "2026-11-14T15:02:16.383Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03518112" }, { "nct_id": "NCT01896999", "title": "Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Classic Hodgkin Lymphoma", "Refractory Classic Hodgkin Lymphoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Brentuximab Vedotin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 146, "start_date": "2014-03-07", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-11-12", "last_synced_at": "2026-11-14T15:02:16.383Z", "location_count": 479, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 303 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01896999" }, { "nct_id": "NCT01349049", "title": "Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "PLX3397", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2011-11-21", "completion_date": "2018-01-09", "has_results": true, "last_update_posted_date": "2020-03-02", "last_synced_at": "2026-11-14T15:02:16.383Z", "location_count": 9, "location_summary": "San Francisco, California • Chicago, Illinois • Baltimore, Maryland + 5 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01349049" }, { "nct_id": "NCT02689284", "title": "Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Gastric Cancer", "Stomach Cancer", "Esophageal Cancer" ], "interventions": [ { "name": "Margetuximab 10 mg/kg", "type": "BIOLOGICAL" }, { "name": "Margetuximab 15 mg", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 95, "start_date": "2016-01", "completion_date": "2021-01", "has_results": true, "last_update_posted_date": "2025-03-17", "last_synced_at": "2026-11-14T15:02:16.383Z", "location_count": 11, "location_summary": "New Haven, Connecticut • Washington D.C., District of Columbia • Chicago, Illinois + 8 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02689284" }, { "nct_id": "NCT01039155", "title": "Azacitidine and Oxaliplatin In Treating Patients With Advanced Cancers Relapsed or Refractory to Any Platinum Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Solid Neoplasm", "Hematopoietic and Lymphoid Cell Neoplasm" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2009-12", "completion_date": "2015-07", "has_results": false, "last_update_posted_date": "2015-10-06", "last_synced_at": "2026-11-14T15:02:16.383Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01039155" }, { "nct_id": "NCT07517315", "title": "Expanded Access to Vodobatinib for Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Not Responded to Previous Treatments", "overall_status": "TEMPORARILY_NOT_AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "CML, Relapsed", "CML, Refractory" ], "interventions": [ { "name": "K0706", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sun Pharma Advanced Research Company Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-11-14T15:02:16.383Z", "location_count": 2, "location_summary": "Augusta, Georgia • Salt Lake City, Utah", "locations": [ { "city": "Augusta", "state": "Georgia" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT07517315" }, { "nct_id": "NCT01915498", "title": "Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hematologic Neoplasms" ], "interventions": [ { "name": "Enasidenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 345, "start_date": "2013-08-27", "completion_date": "2023-10-31", "has_results": true, "last_update_posted_date": "2024-10-22", "last_synced_at": "2026-11-14T15:02:16.383Z", "location_count": 19, "location_summary": "Duarte, California • Stanford, California • Aurora, Colorado + 14 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01915498" } ] }